Cytokinetics
CYTK
126 hedge funds and large institutions have $311M invested in Cytokinetics in 2018 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 42 increasing their positions, 38 reducing their positions, and 18 closing their positions.
17% more capital invested
Capital invested by funds: $266M → $311M (+$45M)
11% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 38
0.71% more ownership
Funds ownership: 68.48% → 69.19% (+0.71%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 18
1% less funds holding
Funds holding: 127 → 126 (-1)
19% less call options, than puts
Call options by funds: $591K | Put options by funds: $731K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12M |
| 2 |
BlackRock
New York
|
+$5.71M |
| 3 |
Millennium Management
New York
|
+$2.99M |
| 4 |
SDIC
South Dakota Investment Council
Sioux Falls,
South Dakota
|
+$2.22M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$1.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$6.17M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.38M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.63M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.73M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.7M |
CYTK Hedge Fund Activity: Q2 2018 in Review
126 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q2 2018, worth a combined $311M — up 17% from $266M a quarter earlier.
Fund positioning in CYTK was balanced in Q2 2018: 18 funds opened new positions, 18 closed out, 42 added to existing stakes and 38 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $12M. The largest seller was Citigroup, cutting an estimated $6.17M.
- 126 institutional investors held Cytokinetics (CYTK) as of Q2 2018, down from 127 in Q1 2018.
- Funds reported $311M of Cytokinetics stock for Q2 2018, up 17% quarter-over-quarter.
- 18 funds opened new Cytokinetics positions in Q2 2018 and 18 closed out, a net change of 0 holders.
- The largest Cytokinetics buyer in Q2 2018 was Great Point Partners, an estimated $12M added.
- The largest Cytokinetics seller in Q2 2018 was Citigroup, an estimated $6.17M sold.
Based on aggregated 13F filings for Q2 2018.